

Laine E Thomas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4952733/publications.pdf>

Version: 2024-02-01

97
papers

5,501
citations

71102

41
h-index

85541

71
g-index

97
all docs

97
docs citations

97
times ranked

8163
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction. Journal of Cardiac Failure, 2022, 28, 191-201.	1.7	6
2	Racial Disparities in Invasive Management for Patients With Acute Myocardial Infarction With Chronic Kidney Disease. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS121011171.	3.9	1
3	Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention. Journal of the American College of Cardiology, 2022, 79, 417-427.	2.8	12
4	Asthma and the Risk of SARS-CoV-2 Infection Among Children and Adolescents. Pediatrics, 2022, 149, .	2.1	14
5	Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMPâ€CHF. Journal of the American Heart Association, 2022, 11, .	3.7	3
6	Impact of the COVID-19 pandemic on patterns of outpatient cardiovascular care. American Heart Journal, 2021, 231, 1-5.	2.7	73
7	RE:â€œADDRESSING EXTREME PROPENSITY SCORES VIA THE OVERLAP WEIGHTSâ€• American Journal of Epidemiology, 2021, 190, 189-190.	3.4	2
8	Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II). American Journal of Cardiovascular Drugs, 2021, 21, 553-561.	2.2	5
9	Black Women Are More Likely Than White Women to Schedule a Uterine-Sparing Treatment for Leiomyomas. Journal of Women's Health, 2021, 30, 355-366.	3.3	9
10	Impact of the Early Phase of the COVID-19 Pandemic on US Healthcare Workers: Results from the HERO Registry. Journal of General Internal Medicine, 2021, 36, 1319-1326.	2.6	52
11	Propensity score weighting for causal subgroup analysis. Statistics in Medicine, 2021, 40, 4294-4309.	1.6	22
12	Covariate adjustment in subgroup analyses of randomized clinical trials: A propensity score approach. Clinical Trials, 2021, 18, 570-581.	1.6	4
13	The Importance of the Design of Observational Studies in Comparative Effectiveness Research: Lessons from the GARFIELD-AF and ORBIT-AF registries. American Heart Journal, 2021, 243, 110-121.	2.7	3
14	Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. Circulation, 2020, 141, 781-783.	1.6	80
15	Using Propensity Score Methods to Create Target Populations in Observational Clinical Research. JAMA - Journal of the American Medical Association, 2020, 323, 466.	7.4	110
16	Short-term quality of life after myomectomy for uterine fibroids from the COMPARE-UF Fibroid Registry. American Journal of Obstetrics and Gynecology, 2020, 222, 345.e1-345.e22.	1.3	35
17	Propensity score weighting under limited overlap and model misspecification. Statistical Methods in Medical Research, 2020, 29, 3721-3756.	1.5	49
18	Overlap Weighting. JAMA - Journal of the American Medical Association, 2020, 323, 2417.	7.4	285

#	ARTICLE	IF	CITATIONS
19	Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19). JAMA Cardiology, 2020, 5, 988.	6.1	16
20	Comparative effectiveness of hysterectomy versus myomectomy on one-year health-related quality of life in women with uterine fibroids. Fertility and Sterility, 2020, 113, 618-626.	1.0	38
21	Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention. Circulation, 2020, 141, 1618-1627.	1.6	84
22	Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). American Heart Journal, 2020, 226, 85-93.	2.7	13
23	Matching with timeâ€dependent treatments: A review and look forward. Statistics in Medicine, 2020, 39, 2350-2370.	1.6	23
24	Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetesâ€Mellitus and HFrEF. JACC: Heart Failure, 2020, 8, 469-480.	4.1	47
25	Addressing Extreme Propensity Scores via the Overlap Weights. American Journal of Epidemiology, 2019, 188, 250-257.	3.4	216
26	Application of net reclassification index to non-nested and point-based risk prediction models: a review. European Heart Journal, 2019, 40, 1880-1887.	2.2	39
27	Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke. JAMA Neurology, 2019, 76, 1192.	9.0	70
28	Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF). American Journal of Cardiology, 2019, 124, 1900-1906.	1.6	19
29	Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the Tj ETQq1 1 0.784314 rgBT ₁₀ /Overlock	1.6	10
30	Separating variability in healthcare practice patterns from random error. Statistical Methods in Medical Research, 2019, 28, 1247-1260.	1.5	0
31	Digoxin and Mortality in Patients Withâ€Atrial Fibrillation. Journal of the American College of Cardiology, 2018, 71, 1063-1074.	2.8	147
32	Health Status Variation Across Practices in Outpatients With Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004668.	2.2	15
33	Lipid Testing and Statin Dosing After Acute Myocardial Infarction. Journal of the American Heart Association, 2018, 7, .	3.7	22
34	Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes. JAMA Cardiology, 2018, 3, 54.	6.1	77
35	Neighborhood Socioeconomic Disadvantage and Care After Myocardial Infarction in the National Cardiovascular Data Registry. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004054.	2.2	30
36	The Comparing Options for Management: PATient-centered REsults for Uterine Fibroids (COMPARE-UF) registry: rationale and design. American Journal of Obstetrics and Gynecology, 2018, 219, 95.e1-95.e10.	1.3	48

#	ARTICLE	IF	CITATIONS
37	Tools for Evaluating and Improving Causal Inference. JAMA Cardiology, 2018, 3, 907.	6.1	4
38	Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Journal of Thrombosis and Thrombolysis, 2018, 46, 435-439.	2.1	9
39	Relationship between baseline physical activity assessed by pedometer count and new-onset diabetes in the NAVIGATOR trial. BMJ Open Diabetes Research and Care, 2018, 6, e000523.	2.8	32
40	Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. Journal of the American Heart Association, 2017, 6, .	3.7	34
41	Hospital Variation in Functional Recovery After Stroke. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	28
42	Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. American Heart Journal, 2017, 185, 140-149.	2.7	54
43	Updated risk factors should be used to predict development of diabetes. Journal of Diabetes and Its Complications, 2017, 31, 859-863.	2.3	5
44	Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). American Heart Journal, 2017, 189, 40-47.	2.7	53
45	Unexplained Variation for Hospitals' Use of Inpatient Rehabilitation and Skilled Nursing Facilities After an Acute Ischemic Stroke. Stroke, 2017, 48, 2836-2842.	2.0	37
46	Transcatheter Versus Surgical Aortic Valve Replacement. Journal of the American College of Cardiology, 2017, 70, 439-450.	2.8	82
47	Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	4.8	29
48	Reassessment of Cardiac Function and Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Myocardial Infarction. Circulation, 2017, 135, 38-47.	1.6	16
49	Assessment of Home-Time After Acute Ischemic Stroke in Medicare Beneficiaries. Stroke, 2016, 47, 836-842.	2.0	67
50	The association of left ventricular ejection fraction with clinical outcomes after myocardial infarction: Findings from the Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry's Get With the Guidelines (GWTG) Medicare-linked database. American Heart Journal, 2016, 178, 65-73.	2.7	54
51	Differences in Short- and Long-Term Outcomes Among Older Patients With ST-Elevation Versus Non-ST-Elevation Myocardial Infarction With Angiographically Proven Coronary Artery Disease. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 513-522.	2.2	42
52	Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. Circulation, 2016, 134, 1122-1124.	1.6	6
53	Patient factors associated with quality of life in atrial fibrillation. American Heart Journal, 2016, 182, 135-143.	2.7	62
54	Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT-AF Registry. Clinical Cardiology, 2016, 39, 119-125.	1.8	6

#	ARTICLE	IF	CITATIONS
55	Stability of International Normalized Ratios in Patients Taking Long-term Warfarin Therapy. JAMA - Journal of the American Medical Association, 2016, 316, 661.	7.4	33
56	Race and Sex Differences in Management and Outcomes of Patients After ST-Elevation and Non-ST-Elevation Myocardial Infarct: Results From the NCDR. Clinical Cardiology, 2016, 39, 585-595.	1.8	64
57	Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. American Journal of Medicine, 2016, 129, 592-599.e1.	1.5	49
58	Timing of First Postdischarge Follow-up and Medication Adherence After Acute Myocardial Infarction. JAMA Cardiology, 2016, 1, 147.	6.1	80
59	Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry. American Heart Journal, 2016, 174, 29-36.	2.7	82
60	Care Transitions After Acute Myocardial Infarction for Transferred-In Versus Direct-Arrival Patients. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 109-116.	2.2	9
61	Association Between Hospital Process Composite Performance and Patient Outcomes After In-Hospital Cardiac Arrest Care. JAMA Cardiology, 2016, 1, 37.	6.1	56
62	Comparisons of Hospitalization Rates Among Younger Atrial Fibrillation Patients Receiving Different Antiarrhythmic Drugs. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 292-300.	2.2	10
63	Cumulative Incidence of Death and Rehospitalization Among the Elderly in the First Year after NSTEMI. American Journal of Medicine, 2015, 128, 582-590.	1.5	35
64	Fibrinolysis Use Among Patients Requiring Interhospital Transfer for ST-Segment Elevation Myocardial Infarction Care. JAMA Internal Medicine, 2015, 175, 207.	5.1	72
65	Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Journal of the American Heart Association, 2015, 4, .	3.7	68
66	Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study. BMJ Open, 2015, 5, e007901.	1.9	7
67	Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation. Circulation, 2015, 131, 488-494.	1.6	224
68	Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 393-402.	2.2	173
69	Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2015, 313, 2433.	7.4	50
70	Cardiac arrest and clinical characteristics, treatments and outcomes among patients hospitalized with ST-elevation myocardial infarction in contemporary practice: A report from the National Cardiovascular Data Registry. American Heart Journal, 2015, 169, 515-522.e1.	2.7	33
71	Association of Patient Enrollment in Medicare Part D With Outcomes After Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 567-575.	2.2	9
72	The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. European Heart Journal, 2015, 36, ehv476.	2.2	316

#	ARTICLE	IF	CITATIONS
73	Modest Associations Between Electronic Health Record Use and Acute Myocardial Infarction Quality of Care and Outcomes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 576-585.	2.2	12
74	Antiarrhythmic Drug Use in Patients <65 Years With Atrial Fibrillation and Without Structural Heart Disease. <i>American Journal of Cardiology</i> , 2015, 115, 316-322.	1.6	23
75	Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>American Heart Journal</i> , 2015, 169, 25-30.	2.7	61
76	Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2015, 36, 1264-1272.	2.2	144
77	Chronic vitamin K antagonist therapy and bleeding risk in ST elevation myocardial infarction patients. <i>Heart</i> , 2015, 101, 264-270.	2.9	0
78	Venous Thromboembolism and Cardiovascular Risk: Results from the NAVIGATOR Trial. <i>American Journal of Medicine</i> , 2015, 128, 297-302.	1.5	9
79	Abstract 17236: Intracranial Hemorrhage in Patients With Atrial Fibrillation in the ARISTOTLE Trial: Clinical Characteristics and Associated Outcomes. <i>Circulation</i> , 2015, 132, .	1.6	0
80	Check It, Change It. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 828-834.	2.2	30
81	Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. <i>European Heart Journal</i> , 2014, 35, 1864-1872.	2.2	303
82	Differences in Short-Term Versus Long-Term Outcomes of Older Black Versus White Patients With Myocardial Infarction. <i>Circulation</i> , 2014, 130, 659-667.	1.6	30
83	Trends in Referral to Cardiac Rehabilitation After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2582-2583.	2.8	61
84	Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2141-2147.	2.8	308
85	Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation. <i>Circulation</i> , 2014, 129, 2005-2012.	1.6	73
86	Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis. <i>Lancet, The</i> , 2014, 383, 1059-1066.	13.7	186
87	Chronic obstructive pulmonary disease and cardiovascular risk: Insights from the NAVIGATOR trial. <i>International Journal of Cardiology</i> , 2014, 176, 1126-1128.	1.7	11
88	Sources of Hospital-Level Variation in Major Bleeding Among Patients With Non-ST-Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 236-243.	2.2	7
89	Amiodarone, Anticoagulation, and Clinical Events in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1541-1550.	2.8	84
90	Do patients treated at academic hospitals have better longitudinal outcomes after admission for non-ST-elevation myocardial infarction?. <i>American Heart Journal</i> , 2014, 167, 762-769.	2.7	16

#	ARTICLE	IF	CITATIONS
91	Response to Letter to the Editor by Lin et al. American Heart Journal, 2014, 167, e21.	2.7	0
92	Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: Results from NAVIGATOR. Metabolism: Clinical and Experimental, 2014, 63, 554-561.	3.4	37
93	Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood, 2014, 124, 3692-3698.	1.4	149
94	Association of Early Physician Follow-Up and 30-Day Readmission After Non-“ST-Segment” Elevation Myocardial Infarction Among Older Patients. Circulation, 2013, 128, 1206-1213.	1.6	43
95	The Value of Statistical Analysis Plans in Observational Research. JAMA - Journal of the American Medical Association, 2012, 308, 773.	7.4	89
96	Outcomes registry for better informed treatment of atrial fibrillation: Rationale and design of ORBIT-AF. American Heart Journal, 2011, 162, 606-612.e1.	2.7	137
97	A Moment-Adjusted Imputation Method for Measurement Error Models. Biometrics, 2011, 67, 1461-1470.	1.4	19